Babacar Ndiaye¹✉, Abdou Diop¹, Mam Coumba Diouf ¹, Omar Gueye ², Malick Ndao², Thierno Abdoulaye Diallo ¹, Chantal Mahou ¹, Abdoulaye Seck ¹,³
¹Medical biology laboratory, Pasteur Institute of Dakar
²Public Health National Laboratory, Thies
³Bacteriology-Virology Laboratory, Cheikh Anta DIOP University, Dakar
Received: Dec 26, 2023/ Accepted: Jan 27, 2023/ Published: Jan 31, 2023
(✉) Corresponding Author: nbabacar9@gmail.com
Abstract
Hepatitis B virus (HBV) infection is a major public health problem in sub-Saharan Africa. Since 2004, Senegal had introduced HBV vaccine in its expanded program of immunization, and in 2016, vaccination at birth was introduced. The aim of this study was to investigate the prevalence of HBV and the immunity of children. This was a retrospective study conducted at medical biology laboratory of Pasteur Institute in Dakar covering data from 2016 to 2020. We measured serological markers (HBsAg, anti-HBc, anti-HBsAb) by ARCHITECTâ automated immunoassay platform (Abbott Diagnostics, Wiesbaden, Germany). Data entry was performed by Excel 2016 (Microsoft, USA), and statistical analysis by STATA 14.0 software (Stata Corp, USA). Bivariate analyses were performed using the chi-square test and a statistically significant difference was retained if p<0.05. A total of 428 children were included with a mean age of 7.57 years, ranging from 6 months to 15 years. The prevalence of HBV was 0.47% (0.0-1.2). HBsAb were found in 372 children or 86.9% (95% CI = 83.9-90.2). The vaccination coverage rate was 82.48% and 4.44% had post-contact immunity. The immunization rate was 62.08% and seroprotection was better in boys (64.01%, p=0.542). The level of seroprotection decreased progressively with age (p=0.001). Hepatitis B is a real public health problem and prevention through vaccination is one of the most effective means of combating the disease. Strengthened strategies are needed to achieve the WHO’s 2030 targets.
Keywords: Hepatitis B, Children, Immunization, Serological markers, HBV vaccine
References
Niang, M. S., Fall, K. S., Mbengue, B., Mbow, M., Diouf, N. N., Boye, O. & Dieye, A. (2017). Immunological status to hepatitis B virus of pregnant women in Dakar, Senegal. Open Journal of Immunology, 7(2), 37-44.
Nelson, N. P., Easterbrook, P. J., & McMahon, B. J. (2016). Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clinics in liver disease, 20(4), 607-628.
World Health Organization. (2009). Hepatitis B vaccines. Weekly Epidemiological Record. 84(40):405-20.
Schütze, T., Bouvet, R., & Le Gueut, M. (2014). Vaccination hépatite B et sclérose en plaques: de l’incertitude médicale à l’indemnisation des victimes. Revue Neurologique, 170(8-9), 520-526.
Breakwell, L., Tevi-Benissan, C., Childs, L., Mihigo, R., & Tohme, R. (2017). The status of hepatitis B control in the African region. The Pan African Medical Journal, 27(Suppl 3).
World Health Organisation. (2016). Combatting Hepatitis B and C to reach elimination by 2030. Geneva. Google Scholar.
Pol, S. (2015). HBV vaccine-the first vaccine to prevent cancer. Nature Reviews Gastroenterology & Hepatology, 12(4), 190-191.
Chiang, C. J., Yang, Y. W., You, S. L., Lai, M. S., & Chen, C. J. (2013). Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. Jama, 310(9), 974-976.
Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., & Sun, Z. (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS medicine, 11(12), e1001774.
Rapport mondial sur l’hépatite, (2017). WHO/HIV/2017.06
Komatsu, H. (2014). Hepatitis B virus: where do we stand and what is the next step for eradication?. World journal of gastroenterology: WJG, 20(27), 8998.
Coppola, N., Corvino, A. R., De Pascalis, S., Signoriello, G., Di Fiore, E., Nienhaus, A. & Lamberti, M. (2015). The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy. BMC infectious diseases, 15, 1-7.
Excler, J. L., Yvonnet, B., Gaye, Y., Monnereau, A., Mangin, J. L., Schlumberger, M. & Sarr, L. C. (1995). Inclusion de la vaccination contre l’hépatite B dans le Programme élargi de vaccination: étude de faisabilité dans la région médicale de Kolda (Sénégal). Cahiers d’études et de recherches francophones/Santé, 5(1), 37-42.
Bekondi, C., Zanchi, R., Seck, A., Garin, B., Giles-Vernick, T., Gody, J. C. & Vray, M. (2015). HBV immunization and vaccine coverage among hospitalized children in Cameroon, Central African Republic and Senegal: a cross-sectional study. BMC infectious diseases, 15, 1-9.
Lô, G., Sow-Sall, A., Diop-Ndiaye, H., Babacar, N., Diouf, N. N., Daffé, S. M. & Touré-Kane, N. C. (2019). Hepatitis B virus (HBV) infection amongst children in Senegal: current prevalence and seroprotection level. Pan African Medical Journal, 32(1).
Chotard, J., Inskip, H. M., Hall, A. J., Loik, F., Mendy, M., Whittle, H., … & Lowe, Y. (1992). The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B. Journal of Infectious Diseases, 166(4), 764-768.
Peto, T. J., Mendy, M. E., Lowe, Y., Webb, E. L., Whittle, H. C., & Hall, A. J. (2014). Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC infectious diseases, 14(1), 1-8.
Cui, F., Shen, L., Li, L., Wang, H., Wang, F., Bi, S., … & Wang, Y. (2017). Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerging infectious diseases, 23(5), 765.
Mondiale de la Santé, O. (2016). Stratégie mondiale du secteur de la santé contre le VIH 2016-2021: vers l’élimination du SIDA (No. WHO/HIV/2016.05). Organisation mondiale de la Santé.
World Health Organization. (2016). WHO-UNICEF estimates of HepB3 coverage. (updated 03/03/2017; cited 2017 04/3/2017).
World Health Organization. (2016). Global compliance with Hepatitis B vaccine birth dose and factors related to timely schedule. A review (cited 2016 November 14, 2016).
Pinto, M., Dawar, M., Krajden, M., Naus, M., & Scheifele, D. W. (2017). Will Infant Hepatitis B Vaccination Protect Into Adulthood?. The Pediatric infectious disease journal, 36(6), 609-615.
McMahon, B. J., Bruden, D. L., Petersen, K. M., Bulkow, L. R., Parkinson, A. J., Nainan, O. (2005). Antibody levels and protection after hepatitis B vaccination: results of a 15-years follow up. Ann Intern Med. 142:333–41.
Gara, N., Abdalla, A., Rivera, E., Zhao, X., Werner, J. M., Liang, T. J. & Ghany, M. G. (2015). Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. Clinical infectious diseases, 60(4), 505-513.
Simons, B. C., Spradling, P. R., Bruden, D. J., Zanis, C., Case, S., Choromanski, T. L. & McMahon, B. J. (2016). A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. The Journal of infectious diseases, 214(2), 273-280.
How to cite this article
Ndiaye, B., Diop, A., Diouf, M. C., Gueye, O., Ndao, M., Diallo, T. A., Mahou, C. and Seck, A. (2023). Prevalence and seroprotection level of hepatitis B virus among children in Dakar, Senegal. Microbial Science Archives, Vol. 3 (1), 6-11. https://doi.org/10.47587/MSA.2023.3102
Licence Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
